Carol Sue Braun

age ~78

from Loomis, CA

Get Report

Also known as:

Carol S Braun
Carol M Braun
Carol S Draun

Phone and address:: 3270 Taylor Rd, Loomis, CA 95650
916 652-6290

Connected to:

Carol Braun Phones & Addresses

3270 Taylor Rd, Loomis, CA 95650 • 916 652-6290
Foresthill, CA
Wheat Ridge, CO
Ardsley, NY
Hanford, CA
Plantation, FL
Riverside, CA
Auburn, CA
Penryn, CA
Santa Cruz, CA

Work

Company:

Kaiser Permanente Medical Group
Address:

14701 E Exposition Ave, Aurora, CO 80012

Education

School / High School:

University Of Colorado School Of Medicine

Ranks

Certificate:

American Board of Obstetrics and Gynecology Certification in Obstetrics & Gynecology

License Records

Medical Doctor

Address:

8949 E Jewell Cir, Denver, CO 80231

License #:

20405 - Active

Issued Date:

Oct 12, 1976

Renew Date:

May 1, 2015

Expiration Date:

Apr 30, 2017

Type:

Physician

Medicine Doctors

Dr. Carol B Braun - MD (Doctor of Medicine)

view source

Hospitals:

Kaiser Permanente Medical Group
14701 E Exposition Ave, Aurora, CO 80012

Education:

Medical Schools
University Of Colorado School Of Medicine

Carol Bartlett Braun

view source

Specialties:

Obstetrics & Gynecology

Education:

University of Colorado

Carol Bartlett Braun, Aurora CO

view source

Specialties:

OB-GYN

Address:

14701 E Exposition Ave, Aurora, CO 80012

Education:

University of Colorado, School of Medicine (Denver) - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Residency - Obstetrics and Gynecology

Board certifications:

American Board of Obstetrics and Gynecology Certification in Obstetrics & Gynecology

Us Patents

Secnidazole For Use In The Treatment Of Bacterial Vaginosis
view source
US Patent:

20210283106, Sep 16, 2021
Filed:

May 31, 2021
Appl. No.:

17/335016
Inventors:

- Baltimore MD, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Assignee:

Lupin Inc. - Baltimore MD
International Classification:

A61K 31/4164
A61K 45/06
C07D 233/94
A61K 31/565
A61K 31/567
A61K 9/00
A61K 9/16
A61K 9/50
Abstract:

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Secnidazole For Use In The Treatment Of Trichomoniasis
view source
US Patent:

20200306228, Oct 1, 2020
Filed:

Jun 15, 2020
Appl. No.:

16/901739
Inventors:

- Baltimore MD, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Richard HOLL - Somerset NJ, US
Assignee:

LUPIN INC. - Baltimore MD
International Classification:

A61K 31/4164
A61K 45/06
C07D 233/94
A61K 31/565
A61K 31/567
A61K 9/00
A61K 9/16
A61K 9/50
Abstract:

Method of treating trichomoniasis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.

Secnidazole For Use In The Treatment Of Trichomoniasis
view source
US Patent:

20200289470, Sep 17, 2020
Filed:

Jun 2, 2020
Appl. No.:

16/890526
Inventors:

- Baltimore MD, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Assignee:

LUPIN INC. - Baltimore MD
International Classification:

A61K 31/4164
A61K 45/06
C07D 233/94
A61K 31/565
A61K 31/567
A61K 9/00
A61K 9/16
A61K 9/50
Abstract:

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of trichomoniasis in a subject in need thereof.

Secnidazole For Use In The Treatment Of Bacterial Vaginosis
view source
US Patent:

20200206192, Jul 2, 2020
Filed:

Mar 12, 2020
Appl. No.:

16/817246
Inventors:

- Baltimore MD, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Richard HOLL - Somerset NJ, US
Assignee:

LUPIN INC. - Baltimore MD
International Classification:

A61K 31/4164
A61K 9/50
A61K 9/16
A61K 9/00
A61K 31/567
A61K 31/565
C07D 233/94
A61K 45/06
Abstract:

Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.

Secnidazole For Use In The Treatment Of Bacterial Vaginosis
view source
US Patent:

20200038372, Feb 6, 2020
Filed:

Sep 27, 2019
Appl. No.:

16/586372
Inventors:

- NEWARK NJ, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Assignee:

SYMBIOMIX THERAPEUTICS, LLC - NEWARK NJ
International Classification:

A61K 31/4164
A61K 45/06
C07D 233/94
A61K 31/565
A61K 31/567
A61K 9/00
A61K 9/16
A61K 9/50
Abstract:

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Secnidazole For Use In The Treatment Of Bacterial Vaginosis
view source
US Patent:

20200022958, Jan 23, 2020
Filed:

Sep 27, 2019
Appl. No.:

16/586339
Inventors:

- NEWARK NJ, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Assignee:

SYMBIOMIX THERAPEUTICS, LLC - NEWARK NJ
International Classification:

A61K 31/4164
A61K 45/06
C07D 233/94
A61K 31/565
A61K 31/567
A61K 9/00
A61K 9/16
A61K 9/50
Abstract:

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Secnidazole For Use In The Treatment Of Bacterial Vaginosis
view source
US Patent:

20190255020, Aug 22, 2019
Filed:

May 3, 2019
Appl. No.:

16/403176
Inventors:

- Newark NJ, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Assignee:

SYMBIOMIX THERAPEUTICS, LLC - Newark NJ
International Classification:

A61K 31/4164
A61K 31/567
A61K 31/565
A61K 9/50
A61K 45/06
A61K 9/00
C07D 233/94
A61K 9/16
Abstract:

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Secnidazole For Use In The Treatment Of Bacterial Vaginosis
view source
US Patent:

20180333391, Nov 22, 2018
Filed:

Jul 30, 2018
Appl. No.:

16/049032
Inventors:

- Newark NJ, US
David PALLING - Glen Ridge NJ, US
Carol J. BRAUN - Ellicott City MD, US
Richard HOLL - Somerset NJ, US
Assignee:

SYMBIOMIX THERAPEUTICS, LLC - Newark NJ
International Classification:

A61K 31/4164
C07D 233/94
A61K 31/567
A61K 9/00
A61K 9/50
A61K 9/16
A61K 31/565
Abstract:

Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.